NAMS earnings: real EPS beat/miss history, analyst consensus Buy, P/E -17.51. Updated 2026-07-23.
NewAmsterdam Pharma (NAMS) Research Hub
NewAmsterdam Pharma (NAMS) trades on NASDAQ, NL in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 22.8 USD (+0.04%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -17.51, market cap 3.70B. This hub links to the full technical, earnings and options research available for NAMS.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, NL |
| Last close | 22.8 USD (+0.04%) |
| 52-week range | 21.23 USD – 37.37 USD |
| Trend regime | Range |
| 14-day RSI | 27.2 (Oversold) |
| Trailing P/E | -17.51 |
| Market cap | 3.70B |
| Dividend yield | 0.00% |
Available research for NAMS
Covered Call on NAMS: how it works, illustrative setup around the real 22.8 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on NAMS: how it works, illustrative setup around the real 22.8 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on NAMS: how it works, illustrative setup around the real 22.8 USD price, max profit/loss, breakeven and when to use it. Educational.
NAMS technical analysis: range, last 22.8 USD, RSI 27.2, 52w range 21.23 USD–37.37 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is NAMS in?
NewAmsterdam Pharma (NAMS) is classified under Healthcare (Biotechnology), listed on NASDAQ, NL.
Is NAMS in an uptrend or downtrend?
As of 2026-09-11, NAMS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is NAMS's trailing P/E ratio?
NAMS's trailing P/E is -17.51, with a market cap of 3.70B. See the earnings research page for full valuation detail.